Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 ascending-dose study of topical TO-210 5% in Japanese patients with acne vulgaris
jRCT2071230128Phase 1Completed
- Sponsor
- Torii Pharmaceutical
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of tapinarof in acne vulgaris (4 arms), sponsored by Torii Pharmaceutical. Primary endpoints: Safety and Pharmacokinetics. Started Mar 2024; status: completed.
02
Drugs
tapinarof
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on jRCT2071230128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230128.